Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds
McCarter, Stuart J. , Lesnick, Timothy G. , Lowe, Val J. , Przybelski, Scott A. , Jack, Clifford R. , Petersen, Ronald C. , Kantarci, Kejal , Vemuri, Prashanthi , Graff‐Radford, Jonathan , Jack, Clifford R , Vemuri, Prashanthi , Kantarci, Kejal , McCarter, Stuart J , Rabinstein, Alejandro A. , Algeciras‐Schimnich, Alicia , Ramanan, Vijay K. , Knopman, David S. , Boeve, Bradley F. , Mielke, Michelle M.

Mayo Clinic

Journal of Alzheimer's Disease | May 3, 2022 | Volume: 87 | Issue: 4 | Pages: 1537-1547

10.3233/jad-220158 | PMID 35527558 Get It

Background: Cerebral microbleeds (CMBs) are a common vascular pathology associated with future intracerebral hemorrhage. Plasma biomarkers of amyloid, tau, and neurodegeneration may provide a screening avenue to identify those with CMBs, but evidence is conflicting. Objective: To determine the association between plasma biomarkers (Aβ40, Aβ42, t-tau, p-tau181, p-tau217, neurofilament light chain (NfL)) and CMBs in a population-based study of aging and whether these biomarkers predict higher signal on Aβ-PET imaging in patients with multiple CMBs. Methods: 712 participants from the Mayo Clinic Study of Aging with T2* GRE MRI and plasma biomarkers were included. Biomarkers were analyzed utilizing Simoa (Aβ40, Aβ42, t-tau, NfL) or Meso Scale Discovery (p-tau181, p-tau217) platforms. Cross-sectional associations between CMBs, plasma biomarkers and Aβ-PET were evaluated using hurdle models and multivariable regression models. Results: Among the 188 (26%) individuals with≥1 CMB, a lower plasma Aβ42/Aβ40 ratio was associated with more CMBs after adjusting for covariables (IRR 568.5 95% CI 2.8–116,127). No other biomarkers were associated with risk or number CMBs. In 81 individuals with≥2 CMBs, higher plasma t-tau, p-tau181, and p-tau217 all were associated with higher Aβ-PET signal, with plasma p-tau217 having the strongest predictive value (r2 0.603, AIC –53.0). Conclusion: Lower plasma Aβ42/Aβ40 ratio and higher plasma p-tau217 were associated with brain amyloidosis in individuals with CMBs from the general population. Our results suggest that in individuals with multiple CMBs and/or lobar intracranial hemorrhage that a lower plasma Aβ42/Aβ40 ratio or elevated p-tau217 may indicate underlying cerebral amyloid angiopathy.
CPI Gastrointestinal Tract Radiology Module 2020
Hansen, Neil J., Wells, Shane A. , Yano, Motoyo , Baheti, Akshay , Revels, Jonathan , Stein, Erica B. , Zafar, Hanna M.

Mayo Clinic

Continuous Professional Improvement | May 3, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.54057/cpi.gi2020 Get It

Correlation of Computed Tomographic Patterns with Morphological Tissue Changes in Idiopathic Pulmonary Fibrosis
Hackett, T.-L., Peterson, S. , Prins, D., Hague, Cameron , Murphy, Darra , LeDoux, S., Chu, F., Xu, FeiFan, Tanabe, N., Ryerson, C.J., Pare, P.D., Coxson, H.O., Colby, Thomas V. , Hogg, J.C., Vasilescu, D.M., Ikezoe, Kohei , Hackett, T.-L., Ledoux, Stacey, Xu, F., Cooper, Jonathan D. , Ryerson, C.J., Paré, P. D., Coxson, H. O., Hogg, JamesC

Mayo Clinic

B28. SEE FOR YOURSELF: EVALUATING LUNG FUNCTION WITH CT AND MRI | May 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A2546-A2546

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2546 Get It

Drug Interactions Affecting Antiarrhythmic Drug Use
Mar, Philip L. , Horbal, Piotr J. , Chung, Mina K. , Dukes, Jonathan W., Ezekowitz, Michael D. , Lakkireddy, Dhanunjaya , Miletello, Mike, Noseworthy, Peter A. , Reiffel, James A. , Horbal, Piotr , Ezekowitz, Michael , Lip, Gregory Y H , Miletello, Mike , Noseworthy, Peter A , Reiffel, James A , Tisdale, James E , Olshansky, Brian , Gopinathannair, Rakesh , Dukes, Jonathan W., Olshansky, Brian , Gopinathannair, Rakesh

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | May 2, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circep.121.007955 | PMID 35491871 Get It

Antiarrhythmic drugs (AAD) play an important role in the management of arrhythmias. Drug interactions involving AAD are common in clinical practice. As AADs have a narrow therapeutic window, both pharmacokinetic as well as pharmacodynamic interactions involving AAD can result in serious adverse drug reactions ranging from arrhythmia recurrence, failure of device-based therapy, and heart failure, to death. Pharmacokinetic drug interactions frequently involve the inhibition of key metabolic pathways, resulting in accumulation of a substrate drug. Additionally, over the past 2 decades, the P-gp (permeability glycoprotein) has been increasingly cited as a significant source of drug interactions. Pharmacodynamic drug interactions involving AADs commonly involve additive QT prolongation. Amiodarone, quinidine, and dofetilide are AADs with numerous and clinically significant drug interactions. Recent studies have also demonstrated increased morbidity and mortality with the use of digoxin and other AAD which interact with P-gp. QT prolongation is an important pharmacodynamic interaction involving mainly Vaughan-Williams class III AAD as many commonly used drug classes, such as macrolide antibiotics, fluoroquinolone antibiotics, antipsychotics, and antiemetics prolong the QT interval. Whenever possible, serious drug-drug interactions involving AAD should be avoided. If unavoidable, patients will require closer monitoring and the concomitant use of interacting agents should be minimized. Increasing awareness of drug interactions among clinicians will significantly improve patient safety for patients with arrhythmias.
Protein‐losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series
Sagray, Ezequiel , Johnson, Jonathan N. , Schumacher, Kurt R. , West, Shawn C. , Lowery, Ray , Simpson, Kathleen E. , West, Shawn , Simpson, Kathleen , Schumacher, K R

Mayo Clinic

Pediatric Transplantation | April 22, 2022 | Volume: 26 | Issue: 5 | Pages: No page available

10.1111/petr.14295 | PMID 35451219 Get It

AbstractBackgroundProtein‐losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.MethodsPatients with Fontan‐related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow‐up were retrospectively identified. Available data related to pre‐ and post‐HTx characteristics and PLE events were collected.ResultsEight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7–21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3–5). PLE recurrences occurred at a median time of 7.5 months after HTx (2–132). Each occurrence was associated with one or more significant clinical events; most commonly cellular‐ or antibody‐mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow‐up at a median time of 4 years (1.3–22.5) after HTx.ConclusionsThis is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
Li, Maggie , Beck, Evan J. , Laeyendecker, Oliver , Eby, Yolanda , Wouters, Camille, Chiklis, Gregory R., Block, William , McKie, Robert O., Joyner, Michael J. , Wiltshire, Timothy D. , Dietz, Allan B. , Gniadek, Thomas J. , Shapiro, Arell, Yarava, Anusha , Lane, Karen , Bloch, Evan M. , Cachay, Edward R. , Huamán, Moisés A. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Gerber, Jonathan M. , Sullivan, David , Wiltshire, Timothy D , Dietz, Allan B , Hanley, Daniel F , Bloch, Evan M , Shoham, Shmuel , Cachay, Edward R , Huaman, Moises A , Levine, Adam C , Paxton, James H , Gerber, Jonathan M , Gebo, Kelly A , Casadevall, Arturo , Sullivan, David J , Joyner, Michael J , Laeyendecker, Oliver , Tobian, Aaron A.R. , Caturegli, Patrizio , Block, William, Hanley, Daniel F. , Shoham, Shmuel , Meisenberg, Barry R. , Anjan, Shweta , Casadevall, Arturo , Pekosz, Andrew

Mayo Clinic

Blood Advances | April 20, 2022 | Volume: 6 | Issue: 12 | Pages: 3678-3683

10.1182/bloodadvances.2022007410 | PMID 35443020 Get It

Abstract The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-δ/pre-ο donor units obtained before March 2021, 20 post-δ COVID-19/postvaccination units, and 1 pre-δ/pre-ο hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], δ, and ο) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to δ or ο, respectively. CCP antibody levels in the upper 10% of the 108 donations as well as 100% of the post-δ COVID-19/postvaccination units and the hyperimmunoglobulin effectively neutralized all 3 variants. High-titer CCP neutralizes SARS-CoV-2 variants despite no previous donor exposure to the variants.
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Samson, Adel , West, Emma J. , Carmichael, Jonathan , Scott, Karen J. , Turnbull, Samantha , Kuszlewicz, Bethany, Dave, Rajiv , Peckham-Cooper, Adam , Tidswell, Emma, Kingston, Jennifer , Johnpulle, Michelle, Jennings, Victoria A. , Stojkowitz, Nicolas, Lusky, Monika, Prasad, Rajendra , Toogood, Giles J. , Bell, John C. , Twelves, Chris , Harrington, Kevin J. , Vile, Richard G. , Pandha, Hardev , Errington‐Mais, Fiona , Ralph, Christy , Newton, Darren , Anthoney, Alan , Melcher, Alan , Collinson, Fiona , Dave, Rajiv V , Bendjama, Kaidre , Bell, John , Twelves, Christopher , Errington-Mais, Fiona , Ralph, Christy , Newton, Darren J , Collinson, Fiona , Melcher, Alan A , Harrington, Kevin , Silva, Bárbara da , Auer, Rebecca

Mayo Clinic

Cancer Immunology Research | April 19, 2022 | Volume: 10 | Issue: 6 | Pages: 745-756

10.1158/2326-6066.cir-21-0171 | PMID 35439304 Get It

Abstract Improving the chances of curing patients with cancer who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, nonrandomized biological end point study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the presurgical intravenous delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases or metastatic melanoma were treated with a single intravenous infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec–associated side effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells. Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with IFNα secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anticancer immunity. In the 2 patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of presurgical oncolytic vaccinia virus-based therapies to stimulate anticancer immunity and increase the chances to cure patients with cancer.
Comparison of Two Diet and Exercise Approaches on Weight Loss and Health Outcomes in Obese Women
Lockard, B , Mardock, M, Oliver, Jonathan M. , Simbo, S, Jagim, Andrew R. , Kresta, Julie, Baetge, Claire, Jung, Y , Koozehchian, M , Khanna, Deepesh , Rasmussen, C, Kreider, Richard B. , Lockard, Brittanie , Jagim, Andrew R , Koozehchian, Majid S , Kreider, Richard B , Byrd, Mike

Mayo Clinic

International Journal of Environmental Research and Public Health | April 18, 2022 | Volume: 19 | Issue: 8 | Pages: 4877

10.3390/ijerph19084877 | PMID 35457744 Get It

Aim: To compare the efficacy of two popular weight loss approaches on weight loss, body composition, and markers of health in sedentary obese women. Methods: In total, 51 sedentary women (age 34.5 ± 7.7 yrs.; weight 90.0 ± 14.5 kg; BMI 34.0 ± 5.1 kg/m2; 46.5 ± 7.0% fat) were matched and randomized to participate in the Weight Watchers® Momentum™ (WW) or Curves® (CV) Fitness and Weight Management program for 16 weeks. Participants in the WW group (n = 27) were provided a point-based diet program, received weekly progress checks and counseling, and were encouraged to exercise. Participants in the CV group (n = 24) followed a menu-based higher protein/low-fat diet (1200 kcal/d) for 1 week; 1500 kcal/d diet for 3 weeks; and 2000–2500 kcals/d for 2 weeks that was repeated three times (except the last segment) while participating in a supervised circuit-style resistance training program (3 d/wk). A general linear model (GLM) with repeated measures was used to analyze data and are presented as mean changes from baseline (mean [UL, LL]). Results: Supervised CV training resulted in greater amounts of vigorous and total physical activity. After 16 weeks, both groups lost weight (WW −6.1 [−7.8, −4.6], CV −4.9 [−6.2, −3.2] kg, p = 0.264). Participants in the CV group observed greater reductions in fat mass (WW −2.9 [−6.7, −0.2], CV −6.4 [−9.2, −3.6] kg, p = 0.081) and increases in lean mass (WW −2.5 [−4.3, −0.7], CV 1.3 [−0.6, 3.2] kg, p = 0.005) resulting in more favorable changes in percent body fat (WW −1.4 [−4.1, 1.2], CV −4.7 [−7.5, −1.8]%, p = 0.098). Both groups observed improvements in peak aerobic capacity and muscular endurance, although bench press lifting volume was greater in the CV group. Those in the CV group experienced a greater increase in HDLc and reduction in the CHL–HDLc ratio and triglycerides. Conclusion: Both interventions promoted weight loss and improvements in fitness and markers of health. The CV program, which included supervised resistance training and higher protein diet menus, promoted greater fat loss, increases in lean mass, and improvements in percent body fat and blood lipids. Trial Registration: clinicaltrials.gov, #NCT04372771, registered retrospectively 1 May 2020.
Progression of rotator cuff tendon pathology in manual wheelchair users with spinal cord injury: A 1-year longitudinal study
Straaten, Meegan G. Van , Barlow, Jonathan D. , Murthy, Naveen S. , Morrow, Melissa M. , Van Straaten, Meegan G , Barlow, Jonathan D , Murthy, Naveen S , Morrow, Melissa M , Jahanian, Omid

Mayo Clinic

The Journal of Spinal Cord Medicine | April 14, 2022 | Volume: 46 | Issue: 3 | Pages: 466-476

10.1080/10790268.2022.2057720 | PMID 35420535 Get It